Indeed, a previous meta-analysis of eight cardiovascular outcome trials that included data from 60,080 participants (72.4% with established CVD) demonstrated that GLP-1 RA therapy can lower the risk of major cardiovascular events (MACEs) by 14%, cardiovascular death by 13%, non-fatal stroke by 16%, hospitalization for heart failure (HF) by 10%, all-cause mortality by 12%, and macroalbuminuria by 26% among individuals with T2DM [12]. Here, GLP1R is linked to stroke disorder.